Head to Head Comparison: Phathom Pharmaceuticals (NASDAQ:PHAT) versus Starpharma (OTCMKTS:SPHRY)

Phathom Pharmaceuticals (NASDAQ:PHAT – Get Free Report) and Starpharma (OTCMKTS:SPHRY – Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, dividends, profitability, earnings, analyst recommendations, risk and valuation.

Analyst Recommendations

This is a summary of current recommendations and price targets for Phathom Pharmaceuticals and Starpharma, as provided by MarketBeat.com.

Phathom Pharmaceuticals presently has a consensus target price of $21.00, suggesting a potential upside of 17.52%. Given Phathom Pharmaceuticals’ stronger consensus rating and higher probable upside, research analysts clearly believe Phathom Pharmaceuticals is more favorable than Starpharma.

Earnings & Valuation

This table compares Phathom Pharmaceuticals and Starpharma”s top-line revenue, earnings per share and valuation.

Starpharma has lower revenue, but higher earnings than Phathom Pharmaceuticals.

Profitability

This table compares Phathom Pharmaceuticals and Starpharma’s net margins, return on equity and return on assets.

Risk & Volatility

Phathom Pharmaceuticals has a beta of 0.43, indicating that its share price is 57% less volatile than the S&P 500. Comparatively, Starpharma has a beta of 0.92, indicating that its share price is 8% less volatile than the S&P 500.

Insider & Institutional Ownership

99.0% of Phathom Pharmaceuticals shares are held by institutional investors. 23.0% of Phathom Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Phathom Pharmaceuticals beats Starpharma on 7 of the 12 factors compared between the two stocks.

About Phathom Pharmaceuticals

(Get Free Report)

Phathom Pharmaceuticals, Inc., biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.

About Starpharma

(Get Free Report)

Starpharma Holdings Limited, a biopharmaceutical company, engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life-science, and other applications worldwide. The company offers VivaGel BV, a non-antibiotic vaginal gel for the treatment of bacterial vaginosis and prevention of recurrent BV; VIRALEZE, an antiviral nasal spray; and VivaGel condom, an antiviral condom. It is also involved in the development of DEP cabazitaxel that is in Phase 2 clinical trial for the treatment of prostate and other cancers, DEP docetaxel that is in Phase 2 clinical trials for the treatment of colorectal and other cancers, DEP irinotecan that is in Phase 2 clinical trials f for the treatment of pancreatic and other cancers; and EP gemcitabine, DEP HER-2 ADC, and DEP HER-2 radiotherapy completed preclinical trials for the treatment of solid cancers. In addition, the company's DEP radiotheranostics development pipeline includes DEP HER2-zirconium, a HER2-targeted radio diagnostic for HER2-positive cancers, such as breast and gastric cancer; and HER2-targeted DEP SN38 ADC, a targeted ADC therapeutic for the treatment of human ovarian cancer. Starpharma Holdings Limited was incorporated in 1997 and is headquartered in Abbotsford, Australia.